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INTRODUCTION
There has been a growing interest in fertility preservation 
(FP) over the past few years. This stems from improved cancer 
survival rates, increasing focus on quality of life throughout 
cancer treatments, continuing advances in assisted reproductive 
technologies (ART), as well as increased awareness about FP. 
A comprehensive FP program has several missions. First and 
foremost, a FP program should provide patients with timely 
and comprehensive FP consultations. Second, it should offer 
a comprehensive range of appropriate FP treatments. Third, it 
should employ a multidisciplinary approach for these medi-
cally complicated patients. Fourth, it should provide long-term 
care for these cancer patients, who may have unique issues 
surrounding contraceptive needs, reproductive goals, and 
menopausal symptoms. Finally, it should serve as a resource 
of up-to-date FP information for healthcare providers. 
Setting up a successful FP program is crucial to fulfilling 
these missions. Recently, several studies have determined 
the importance of patient-centered communication in FP [1]. 
Effective communication has been expressed as a goal for 
both compassionate and quality healthcare [2], and is even 
more important in this vulnerable patient population grap-
pling with a new cancer diagnosis as well as fertility concerns. 
When developing a FP program, it is essential to utilize an 
interdisciplinary team, which can include oncologists, fertility 
specialists, embryologists, and mental health professionals. 
Also, procedural and institutional policies or regulations may 
be required to set up a clear plan for patient flow. 
In this review, we discuss unique challenges in FP which 
should be considered before setting up a FP program, 
limitations of current FP programs, and key factors to build a 
successful FP program. 
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Over 150,000 reproductive age individuals face fertility-threatening cancer treatments each year. Improved detection and 
treatment of cancer in reproductive-age patients have greatly increased the long-term survival and made it possible for these 
individuals to consider their long-term quality-of-life after cancer including having biologic offspring. Various methods of fertility 
preservation (FP) are now available for both males and females. In order to maximize FP options available to patients facing 
imminent gonadotoxic therapies, it is crucial that women have quick access to FP care and that providers expedite FP strategies. 
The overarching goal of a clinical FP program is to help patients and their physicians consider the impact of treatment on future 
fertility and facilitate FP efforts in what is often a limited time period before cancer treatment begins.
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UNIQUE CHALLENGES IN FP DICISION MAKING
There are several challenges inherent in decisions regarding 
FP. First, due to the time-sensitive nature of FP treatments, 
information-gathering and assimilation needs to happen 
rapidly. The most effective FP options (embryo, oocytes, and 
sperm banking) are those that are made available to cancer 
patients before treatment begins. In the American Society 
of Clinical Oncology (ASCO) guidelines, it was suggested 
that patients who are interested in FP should consider their 
options as soon as possible to maximize the likelihood of 
success [3]. The American Society of Reproductive Medicine 
(ASRM) guidelines also state that unless interested patients 
are properly referred before treatment, options for later repro-
duction may be lost [4]. However, there is often not enough 
time for decision making and completion of FP treatments 
before cancer treatments begin. For example, in breast cancer 
patients, it takes approximately 2 months between cancer 
diagnosis and the initiation of chemotherapy [5]. However, if 
neoadjuvant chemotherapy is planned, the interval between 
diagnosis and initiation of chemotherapy is usually only 1 
month [5]. Moreover, although a FP treatment protocol takes 
approximately 2 weeks, initiation depends on the timing of 
the menstrual cycle and 14 days is likely insufficient time for 
FP treatment. Patients with hematologic cancers are often 
critically ill with coagulopathy or neutropenia which make 
immediate FP challenging. 
Second, the complexity of the topics involved with FP adds 
challenges for patients to make fast and high-quality decisions. 
Poor FP knowledge and comprehension in patients prior to 
and after FP consultation has been reported [6,7]. Even the 
language used during an FP consultation is highly specialized, 
and can require comprehension of complex topics such as 
probabilities, embryology, and female anatomy and hormonal 
patterns. Discussion about FP options is more complex 
because each FP option (egg, embryo, and ovarian tissue 
cryopreservation) carries unique risks as well as varying prob-
abilities of outcome. In addition, outcomes depend on various 
factors such as the dose and duration of cancer treatment, the 
age of the patient, the patient’s baseline ovarian reserve when 
treatment begins, etc [8]. Finally, since these patients have just 
been told that they have cancer, they are often on the verge of 
information-overload, with the FP topic adding to their burden. 
Third, FP treatments can be a significant financial burden for 
patients. Despite growing evidence of reproductive dysfunc-
tion resulting from cancer treatments, FP is not covered under 
most insurance plans in the US [9]. No states mandate cover-
age for FP for cancer patients prior to treatment. While some 
insurance does cover infertility treatments, patients at risk for 
iatrogenic infertility are different from patients treated for in-
fertility (defined as the inability to conceive after 12 ovulatory 
months of unprotected sexual intercourse). Cancer patients 
may not have infertility at the time of diagnosis, but they need 
to undergo FP services prior to initiation of cancer treatments, 
which may increase the risk of becoming infertile in the future. 
For patients paying out-of-pocket for FP treatments, this can 
cost thousands of dollars, and often this charge must be paid 
before the FP treatments occur.
Fourth, FP treatment requires a multidisciplinary medical 
team and inter-professional approach. An inter-professional 
healthcare approach is a process by which two or more 
professionals collaborate to provide integrated and cohesive 
patient-care to address the needs of their population [10]. Inter-
professionality involves continuous interaction, open com-
munication, knowledge sharing, understanding of professional 
roles and common health goals. Diverse expertise is required 
to discuss and undertake FP options in young cancer patients 
facing fertility-threatening therapy, including providers such as 
a fertility specialist, oncologist, urologist, pathologist, genetic 
counselor, mental-health professionals, social worker, financial 
counselor, etc. To provide timely FP options, it is essential 
to coordinate diverse expertise in terms of time, space and 
medical treatments which is usually challenging and requires 
institutional support to achieve. 
LIMITATIONS OF CURRENT FP PROGRAM
1. Low referral rate
There are several studies querying oncologists about referral 
to fertility specialist. A nationwide survey of oncologists found 
that even though 95% oncologists report that they routinely 
discuss fertility consequences of cancer treatments, over half 
(61.1%) rarely or never refer patients to FP consultation with 
a fertility specialist [11]. In the same study, 30% of oncologists 
responded that they rarely consider a woman’s desire for fu-
ture fertility when planning treatment [11]. In a retrospective 
cohort study, only 20.6% of cancer patients who were eligible 
for FP consultation received it [12]. Another study evaluating 
pediatric oncologists’ attitude toward FP reports that while 
they acknowledge the importance of addressing FP, less than 
half reported referring male patients and only 12% reported 
referring female patients to a fertility specialist prior to treat-
ment [13].
The reasons why many physicians are reluctant to endorse 
FP even with national guideline recommendations in place 
include lack of physicians’ knowledge about fertility, their 
perception that FP may not be a priority for certain patients 
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(parous patients, older women, etc), and physicians’ lack of 
adequate FP referral information [14]. Oncologists’ attitude 
toward FP is significant in patients’ decision making as these 
vulnerable patients are strongly influenced by the messages 
they receive from their oncology team [15]. Another obstacle 
of referral to fertility specialist is the oncologists’ focus on initial 
cancer treatments. While prompt and appropriate treatments 
are essential, oncologists may focus most of their attention 
on these vital immediate issues, and minimal focus on future 
complications, such as infertility [14]. However, the ability to 
have biological children in the future is extremely important to 
a vast majority of cancer patients [16]. It is important for these 
patients to be aware of the risk of infertility and to be able to 
make the choice to pursue or forego FP independently on the 
basis of information provided by health care providers. 
2. Low treatment rate
Aside from the low referral rate to fertility specialists, low 
treatment rate (egg or embryo banking) is a significant 
issue of current FP programs. Low treatment rate may be an 
inevitable consequence of all of the challenges to FP men-
tioned above, such as the narrow time window for FP prior 
to cancer treatment, no available insurance coverage for FP 
treatment and low referral rate to FP consultation. In a recent 
study investigating reproductive age breast cancer patients, 
it was reported that only 58% of patients who pursued FP 
consultation received FP treatments (egg, embryo or ovarian 
tissue cryopreservation) [17]. Considering the low referral rate 
to FP consultation mentioned above, the absolute number 
of patients who pursue FP treatments is quite small. Specifi-
cally, age, income, cancer stage and pursuing neoadjuvant 
chemotherapy were significantly associated with pursuing FP 
treatment [5]. Interestingly, women who received neoadjuvant 
chemotherapy were significantly less likely to pursue FP treat-
ments. This finding is significant because cancer treatment 
plans may be modifiable and the survival gain of neoadjuvant 
chemotherapy in early stage breast cancer has not been vali-
dated [18]. This reinforces the importance of inter-professional 
collaboration to coordinate medical and FP treatments to ap-
propriately maximize a patient’s opportunity for future fertility. 
Financial barriers are a crucial inhibiting factor of FP treat-
ments. As mentioned above, FP is may not be covered under 
insurance plans and in vitro fertilisation (IVF) can be expensive. 
Some financial support programs for FP treatments might be 
helpful. Patients may consider applying for a financial assis-
tance programs such as Fertile Hope’s Sharing Hope Program 
or Walgreen’s Heart Beat program. Also, some fertility centers 
in the US have a discounted package price for cancer patients 
undergoing FP treatments. 
3. Lack of communication with patients and among 
disciplines
Several factors are involved in making a high-quality medical 
decision including acquisition of information and evaluation 
of one’s personal values or attitudes [19,20]. A thorough un-
derstanding of the disease and treatment options is essential 
to make high-quality decisions [21]. In addition, a patient’s 
participation in decision-making with her healthcare provider 
has been shown to lead to more favorable patient outcomes 
[22,23]. Importantly, all these steps are based on the efficient 
communication between patients and healthcare providers. 
However, there are several unique factors that may hinder 
conversations between patients and healthcare providers 
regarding FP options. 
Prior studies have highlighted socioeconomic disparities in 
referral patterns for FP consultation [12,24]. FP treatments can 
be costly; economic and social resources likely play a role in 
determining which groups are able to consider fertility after 
cancer treatments. Ideally, all interested patients, regardless 
of socioeconomic status, would have access to high quality 
information about FP. Unfortunately, due to insurance cover-
age and costly FP options, some patients may not be able to 
consider all treatment options. Given that there is inequality 
in referral patterns for FP consultation, some patients are not 
even given the opportunity for exposure to the field. One 
study showed that oncologists reported that they would be 
less likely to refer men for sperm banking who were human 
immunodeficiency virus (HIV)+ or openly homosexual [25]. 
Low access to FP was reported in women who identified with 
a sexual orientation other than heterosexual, despite having 
no differences in childbearing desires compared with women 
identifying as heterosexual [24]. 
Given the extreme time pressure about FP, prior exposure to 
the general topics regarding FP can be integral to enhance the 
communication between healthcare providers and patients. A 
study showed that previous exposure to FP information (high-
quality websites, such as Fertile Hope, etc) prior to formal FP 
consultation is associated with better comprehension about 
FP treatment options, ideally resulting in a more productive 
conversation with a fertility specialist [6]. 
KEY TO A SUCCESSFUL FP PROGRAM
1. Strong connection between oncologists and fertility 
specialists 
A strong connection between the oncology team and the 
fertility specialist is required for a comprehensive FP program. 
Oncologists’ support for FP treatment is important in several 
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aspects. First, FP process begins with oncologists addressing 
the possibility of infertility with patients who face fertility-
threatening therapies before or during their reproductive years. 
In a recent study, a higher referral rate was shown in breast 
cancer patients compared to patients with other cancers [12], 
and it was speculated that a strong collaboration between 
breast oncologists and fertility specialists in that institution 
might contribute the higher referral rate. Second, it is well 
known that the primary physician’s support and opinion 
have a significant influence on patient’s decision making [26]. 
Finally, since FP always occurs in conjunction with primary 
cancer treatments, open communication between the fertility 
specialist and oncology team is crucial, especially if modifica-
tions are needed for the treatment plans. For example, a recent 
report demonstrated a lower FP utilization rate in a center 
where neoadjuvant chemotherapy has a broader use under 
research protocols compared to other centers [5]. In this case, 
a trade-off existed between pursuing FP treatments versus 
experimental neoadjuvant chemotherapy which would not 
permit the time necessary for FP. Ideally, if survival is equivalent 
between two treatment plans, a patient’s desire for FP should 
be strongly considered and supported by her oncology team. 
There may be several ways to increase oncologists’ support 
for FP treatments. Improved FP education among the oncol-
ogy team (via Grand Rounds, informal educational sessions, 
distribution of FP educational materials and resources provid-
ers and patients, etc.) could help allow oncologists to be more 
involved and make them aware of new developments in FP. 
At the institutional level, establishing policies that encourage 
patient education about FP as a required part of the consulta-
tion and treatment consent process could improve patients’ 
awareness about FP. For example electronic medical records 
could flash an alert for all newly diagnosed reproductive-aged 
cancer patients to discuss and offer FP consultation.
2. Building a FP team
Early identification of key medical contacts facilitates the 
navigation of patients across specialties within the tight 
timelines necessary for FP in cancer patients. It is important 
that FP services and practices are clearly identified in order to 
facilitate referrals of newly diagnosed cancer patients by the 
oncology team members. For most FP programs based on 
multidisciplinary team work, FP consultations can occur within 
24-72 hours of referral. 
Most often, the medical FP team is initially assembled by 
a reproductive endocrinologist or an oncologist. An experi-
enced anesthesia team may play a central role in evaluating 
patients for surgical FP procedures. On occasion, FP patients 
pose complex medical scenarios that require advanced 
anesthesia planning. The pathologist is a crucial contact for 
discussing disposition of ovarian and testicular tissue obtained 
for banking. Laboratory personnel who are highly experienced 
in clinical tissue banking are key members of FP team to 
freeze cells or tissues. Genetic counselors can help patients 
determine heritable conditions that patients may transmit 
to their offspring. Finally, mental health professionals can 
help patients and their families with counseling needs. They 
can discuss various ethical and legal issues to set a realistic 
expectation of FP treatment and provide emotional support 
which are usually beyond the scope of fertility specialists and 
oncologists. 
Establishing an FP patient navigator position can significantly 
reduce the barriers between patients and specialists [4]. They 
play a role to shepherd patients and to ensure that patients 
do not get lost between the complex specialties. Within 
the multidisciplinary team setting, the FP patient navigator 
bridges institutional and disciplinary boundaries so that can-
cer patients are able to receive timely information regarding 
FP options. Also they serve as the primary contact for patients 
and clinicians. This function of the patient navigator makes it 
possible for patients to make well-informed decisions prior to 
the beginning of cancer treatment. 
3. Design of FP consultation 
FP consultation with a fertility specialist is a patients’ main 
informational resource regarding fertility and FP options. In 
a recent survey study evaluating female cancer patients who 
pursued FP consultation, 100% of patients answered that FP 
consultation was the most helpful resource for information 
and 73% of patients made up their mind about treatment 
after the consultation [16]. Because, in most cases, only one FP 
appointment occurs because of time constraints, it is crucial 
that this single visit is as efficient as possible to allow for 
information gathering. 
Utilization of a decision aid as a part of FP consultation can 
potentially help patients better understand the complex 
topics [27]. Patient decision aids are tools that help people 
become involved in decision making by making explicit the 
decision that needs to be made, providing information about 
the options and outcomes, and by clarifying personal values 
[28]. The efficacy of decision aids in medical decision making 
has been validated in various diseases including cancer [29]. 
Studies investigating breast cancer patients who pursued 
breast reconstruction surgery found that patients who used 
an interactive digital decision aid demonstrated greater 
factual knowledge, reduced anxiety, and increased postopera-
tive satisfaction compared with patients given preoperative 
instruction using standard methods alone [29,30]. Pre- and 
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postconsultation exposure to informative resources such as 
brochures and websites about FP options may be helpful, 
too. Practically speaking, patients have to be informed how to 
access these resources and a patient navigator or members of 
the oncology team could assist in providing this information. 
Also, having a brief discussion with a patient navigator prior to 
FP consultation may help to make a complex FP topic more un-
derstandable and accessible. To allow patients to make a high-
quality decision, it is essential to understand their decision-
making process. Various factors such as social status, language 
barriers, financial concerns, and cultural background can be 
related to a patient’s medical decision making. In a recent study, 
decision-making about FP treatment appears to be significantly 
impaired in patients grappling with financial concerns and 
when the opportunity to ask questions was not felt to be 
sufficient [16]. To minimize decisional conflict, it is essential to 
identify and discuss the unique factors that individual patients 
find challenging about FP. Having a follow-up visit or additional 
contact with a fertility specialist after the initial FP consultation 
was found to be significantly associated with lower decisional 
conflict [7]. Follow-up communication via phone or email may 
be ideal and realistic under the time pressure. 
SPECIAL CONSIDERATION IN FP FOR PATIETNS WITH 
GYNECOLOGIC CANCERS
FP in patients with gynecologic cancers can be challeng-
ing-gynecologic cancers are heterogeneous, requiring a 
unique approach for each situation. For now, conservative 
management is the only FP option in patients with ovarian 
cancers [31-34], and borderline ovarian tumors [35,36]. In 
cervical cancer patients, simple or radical trachelectomy may 
be an option for FP in patients with early stage disease. Egg 
or embryo cryopreservation can be offered to some patients 
who will receive pelvic radiation therapy or chemotherapy. 
However, the oocyte retrieval procedure can be challenging 
because there is risk of bleeding and/or reseeding cancer 
cells if the aspiration needle traverses the tumor. FP options in 
endometrial cancer are currently limited to hormonal meth-
ods. Many studies reported favorable pregnancy outcome 
after hormonal treatment in endometrial cancer patients, 
however the total number of patients remains low [37-42]. 
Options such as ovarian tissue cryopreservation and IVF 
with in vitro maturation may be options, though they are 
considered experimental, with limited data about rates of 
future conception. As endometrial cancer is linked to obesity 
and anovulation, many women with the diagnosis may have 
primary or secondary infertility and would require assistance 
to conceive regardless [42]. However, the safety of pregnancy 
and ART after hormonal treatment, particularly in the case of a 
hormonally responsive tumor, is unclear. 
Since there are no randomized clinical trials studying FP in 
gynecologic cancer patients, patients who desire FP should 
clearly understand that data regarding outcome are very 
limited, especially the feasibility and safety of FP techniques 
including commonly used FP techniques such as oocyte or 
embryo cryopreservation. One study found that the referral 
rate to a fertility specialist was the lowest in gynecologic 
cancer patients [12], perhaps because the gynecologist-onco-
logist is more comfortable in discussing FP than oncologists 
in other disciplines. However, these patients may benefit 
from a formal consultation with a fertility specialist to discuss 
other FP options and the difficulty and implications of getting 
pregnant after conservative cancer treatments. In many gyne-
cologic cancer cases, final diagnosis and staging are often not 
made until after fertility-damaging surgery has occurred; thus 
earlier patient education and evaluation through FP consulta-
tion is important. 
CONCLUSION
While more FP options now exist for reproductive-age can-
cer patients, access to these services continues to be limited. 
A tremendous number of individuals need to be involved to 
move a patient from cancer diagnosis to completion of FP 
in a short period of time. While caring for FP patients can be 
challenging, helping appropriate patients pursue FP options is 
important because it can give patients a sense of control over 
their reproductive options and hope for the future. For this 
reason, there has been a continuous movement to expand 
the FP program to all comprehensive cancer centers in US 
over the past few years.
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